ORLADEYO® (berotralstat) Approved in Mexico

Rhea-AI Summary

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that COFEPRIS in Mexico approved ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The drug is now approved in four countries in the pan-Latin America region. BioCryst collaborates with Pint Pharma to bring the therapy to HAE patients in need.

Positive

• Approval of ORLADEYO in Mexico expands market presence in the pan-Latin America region.

• ORLADEYO provides a new treatment option for people suffering from hereditary angioedema.

• Exclusive collaboration with Pint Pharma enhances distribution network in LATAM.

Negative

• None.

Insights

Medical Research Analyst

ORLADEYO's approval by COFEPRIS marks a significant expansion for BioCryst Pharmaceuticals into the Mexican market for the treatment of hereditary angioedema (HAE), a rare and potentially life-threatening condition. This move should enhance the company's revenue stream, as Mexico represents a new frontier for patient reach and can have a multiplier effect when considering the potential uptake in other Latin American countries where the drug has been approved. The collaboration with Pint Pharma is strategic, leveraging their regional expertise to effectively navigate the complexities of local market registrations, distribution and commercialization. The partnership optimizes resource allocation by allowing BioCryst to focus on development and production while Pint Pharma manages the market-specific tasks. This approach can lead to a more efficient capital deployment and potentially quicker uptake of ORLADEYO in the market. Overall, the approval may lead to a positive adjustment in revenue forecasts and should be monitored for its effect on the earnings trajectory of BioCryst.

Market Research Analyst

The approval of a novel therapy like ORLADEYO in Mexico enhances BioCryst's competitive positioning within the HAE therapeutic area. This is particularly relevant considering that treatment options in Latin America may be limited and the approval could signal increased accessibility for patients. The prophylactic nature of the treatment, which reduces the frequency of HAE attacks, aligns with a growing trend in the pharmaceutical industry towards preventative healthcare measures, which can improve patient outcomes and reduce long-term healthcare costs. As a first-to-market oral therapy in Mexico, ORLADEYO could command a significant market share and establish brand loyalty early on. It is important for investors to keep an eye on the market adoption rate and the potential impact on BioCryst's market valuation. Additionally, the company's ability to capitalize on this approval will be indicative of their international market penetration capabilities, which is a valuable aspect for investors considering long-term growth potential.

RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO^® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.

“With this decision by COFEPRIS, ORLADEYO is now approved in four countries in the pan-Latin America region. We are proud to work with our partner, Pint Pharma, to bring our oral, once-daily prophylactic therapy to people living with HAE who are in need of new treatment options in Mexico and throughout LATAM,” said Charlie Gayer, chief commercial officer of BioCryst.

BioCryst has an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO in the pan-Latin America region. Under the terms of the agreement, Pint is responsible for obtaining and maintaining all marketing authorizations and for commercializing ORLADEYO in LATAM. ORLADEYO has previously been approved in this region by regulatory agencies in Chile, Argentina and Brazil.

About ORLADEYO^® (berotralstat)
ORLADEYO^® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.

U.S. Indication and Important Safety Information

INDICATION
ORLADEYO^® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

Limitations of use
The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation.

IMPORTANT SAFETY INFORMATION
An increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent.

The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.

A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C).

Berotralstat is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein. P-gp inducers (eg, rifampin, St. John’s wort) may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO.

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO.

The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established.

There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.

To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding BioCryst’s plans and expectations for ORLADEYO. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s ability to successfully implement its commercialization plans for ORLADEYO, which could take longer or be more expensive than planned; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; risks related to government actions, including that decisions and other actions, including as they relate to pricing, may not be taken when expected or at all, or that the outcomes of such decisions and other actions may not be in line with BioCryst’s current expectations; the commercial viability of ORLADEYO, including its ability to achieve market acceptance; the FDA, COFEPRIS or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay, or withdraw market approval for products and product candidates; BioCryst’s ability to successfully manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s forward-looking statements.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com